Literature DB >> 836214

Periocular injection of corticosteroids: an experimental evaluation of its role in the treatment of corneal inflammation.

H M Leibowitz, A Kupferman.   

Abstract

The present experiments demonstrate that subconjunctivally injected corticosteroids are less effective in suppressing corneal inflammation than are topically instilled corticosteroids. Topical administration of 6.5 mg of prednisolone acetate over a 30-hour period reduced corneal inflammatory activity by 52%. Subconjunctival injection of 50 mg of the same steroid, also given over a 30-hour period, yielded a 15% reduction in corneal inflammation. A fourfold increase (200 mg) in the quantity of prednisolone acetate injected subconjunctivally resulted in a nonsignificant (P less than .05) increment (24%) in anti-inflammatory effect. Dexamethasone sodium phosphate achieved a 30% reduction in corneal inflammation, the maximum effect observed after subconjunctival administration. The data suggest that different modes of corneal penetration are involved after drug delivery via the two routes. Concurrent administration of corticosteroids by the topical and subconjunctival routes seemingly produced an additive anti-inflammatory effect.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 836214     DOI: 10.1001/archopht.1977.04450020112019

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  7 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Pharmacokinetics of ophthalmic corticosteroids.

Authors:  C N McGhee
Journal:  Br J Ophthalmol       Date:  1992-11       Impact factor: 4.638

3.  Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.

Authors:  Bing Wang; Yating Tang; Yumin Oh; Nicholas W Lamb; Shiyu Xia; Zheng Ding; Baiwei Chen; María J Suarez; Tuo Meng; Vineet Kulkarni; Charles G Eberhart; Laura M Ensign; Walter J Stark; Justin Hanes; Qingguo Xu
Journal:  Nanomedicine       Date:  2019-01-21       Impact factor: 5.307

Review 4.  Therapeutic implications of nanomedicine for ocular drug delivery.

Authors:  Tuo Meng; Vineet Kulkarni; Russell Simmers; Vikram Brar; Qingguo Xu
Journal:  Drug Discov Today       Date:  2019-05-15       Impact factor: 7.851

Review 5.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

6.  Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.

Authors:  Lixia Luo; Jin Yang; Yumin Oh; Matthew J Hartsock; Shiyu Xia; Yoo-Chun Kim; Zheng Ding; Tuo Meng; Charles G Eberhart; Laura M Ensign; Jennifer E Thorne; Walter J Stark; Elia J Duh; Qingguo Xu; Justin Hanes
Journal:  J Control Release       Date:  2019-01-17       Impact factor: 9.776

Review 7.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.